Investigational drug · Phase 2
Enobosarm
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity & Overweight, Mobility Disability, HOMA-IR.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
17
Any phase or sponsor naming "Enobosarm"
First trial start
2024
Apr 29, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Enobosarm", any sponsor or status.
- Phase 212
Conditions studied
As listed on its trial records.
- Obesity & Overweight
- Mobility Disability
- HOMA-IR
- Muscle Loss
- Obesity
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Enobosarm" as an intervention, largest first.
- Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary IncontinencePivotal-lookingCompleted
GTxIndustry
NCT03241342 · 491 participants · Start Aug 21, 2017 · Primary completion Sep 21, 2018
Drug: GTx 024; Placebo · For: Stress Urinary Incontinence
Sites: Homewood, Alabama; Mobile, Alabama; Anchorage, Alaska · 62 sites in all
- Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line PlatinumPivotal-lookingCompleted
GTxIndustry
NCT01355497 · 330 participants · Start Jul 2011 · Primary completion May 2013
Drug: GTx-024; placebo · For: Muscle Wasting; Non-Small Cell Lung Cancer
Sites: Birmingham, Alabama; Scottsdale, Arizona; La Jolla, California · 30 sites in all
- Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingCompleted
GTxIndustry
NCT01355484 · 321 participants · Start Jul 2011 · Primary completion May 2013
Drug: GTx-024; placebo · For: Muscle Wasting; Non Small Cell Lung Cancer
Sites: Birmingham, Alabama; Long Beach, California; Aventura, Florida · 27 sites in all
- Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight LossPivotal-lookingActive, not recruiting
Veru Inc.Industry
NCT07446998 · 239 participants · Start Mar 26, 2026 · Primary completion Oct 2027
Drug: Enobosarm; Semaglutide (Wegovy) weekly injection · For: Obesity & Overweight; Mobility Disability; HOMA-IR
Sites: Phoenix, Arizona; Doral, Florida; Miami, Florida · 13 sites in all
- Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight MgmtPivotal-lookingCompleted
Veru Inc.Industry
NCT06282458 · 168 participants · Start Apr 29, 2024 · Primary completion Apr 11, 2025
Drug: Enobosarm; Semaglutide · For: Muscle Loss; Obesity
Sites: Anniston, Alabama; Cullman, Alabama; San Diego, California · 14 sites in all
- Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.Pivotal-lookingCompleted
GTxIndustry
NCT00467844 · 159 participants · Start May 2007 · Primary completion Sep 2008
Drug: GTx-024; GTx-024 and 1 more · For: Cachexia
Sites: Anchorage, Alaska; Fayetteville, Arkansas; Corona, California · 52 sites in all
- Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast CancerPivotal-lookingCompleted
GTxIndustry
NCT02463032 · 136 participants · Start Aug 2015 · Primary completion Mar 2019
Drug: GTx-024 · For: ER+ and AR+ Breast Cancer
Sites: Fort Lauderdale, Florida; Boston, Massachusetts; Billings, Montana · 4 sites in all
- Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast CancerPivotal-lookingTerminated
Veru Inc.Industry
NCT04869943 · 52 participants · Start Oct 12, 2021 · Primary completion Jan 9, 2024
Drug: Enobosarm; Exemestane · For: Metastatic Breast Cancer
Sites: Chandler, Arizona; Gilbert, Arizona; Glendale, California · 54 sites in all
GTxIndustry
NCT02368691 · 32 participants · Start Jun 2015 · Primary completion Sep 22, 2017
Drug: GTx-024 · For: Triple Negative Breast Cancer
Sites: Fort Lauderdale, Florida; Lakeland, Florida; Miami, Florida · 7 sites in all
GTxIndustry
NCT01616758 · 22 participants · Start Apr 2013 · Primary completion Jun 2014
Drug: GTx-024 9mg · For: Metastatic Breast Cancer
Sites: Miami, Florida; Peoria, Illinois; Boston, Massachusetts · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- An Update on the Role of Androgens and Androgen Receptor in Triple-Negative Breast Cancer.
Cortes BC, Queiroga FL, Illera JC, et al. · Cells 2026
- Sarcopenia in Aging: Pathogenesis, Diagnosis, and Emerging Therapeutic Frontiers.
Jeyaraman M, Jeyaraman N, Nallakumarasamy A, et al. · Mol Imaging Biol 2026
- Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes.
Aimelet V, Holst JJ · Diabetes Obes Metab 2026
- Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss.
Arora G, Conde KR, Desouza CV · J Clin Med 2026
- Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions.
von Haehling S, Sato R, Langer H, et al. · J Cachexia Sarcopenia Muscle 2025
- Current Status and Advances in Anti-Androgen Therapy for Triple-Negative Breast Cancer.
Li JB, Xia WF · Curr Med Sci 2025
Also in development for Obesity & Overweight
- BofanglutideGZR18, BofanglutidaPhase 311 trials
Gan & Lee Pharmaceuticals. · Type 2 Diabetes Mellitus (T2DM), Obstructive Sleep Apnea (OSA), Obesity/Overweight in Adult
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- LUM-201Phase 36 trials
Lumos Pharma · Growth Hormone Deficiency, Growth Hormone Deficiency (GHD), Obesity & Overweight
- HDM1005 1Phase 34 trials
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Type 2 Diabetes, Obesity & Overweight
- HDM1005 2Phase 34 trials
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Type 2 Diabetes, Obesity & Overweight
- SemagludtidePhase 32 trials
Lumos Pharma · Obesity & Overweight, Early Alzheimer's Disease
- BIO101Phase 21 trial
Biophytis · Muscle Wasting, Obesity & Overweight, Obesity
- ERX1000Phase 21 trial
ERX Pharmaceuticals · Obesity & Overweight
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.